Biosergen AS Net Assets
Biosergen AS net assets. Based on the latest financial reports, Biosergen AS (BIOSGN) has net assets worth Skr8.12 Million SEK (≈ $873.52K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr21.16 Million ≈ $2.28 Million USD) and total liabilities (Skr13.04 Million ≈ $1.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Biosergen AS equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr8.12 Million |
| % of Total Assets | 38.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -59.88% |
| 10-Year Change | N/A |
| Growth Volatility | 986.47 |
Net Assets of Biosergen AS (2019–2025)
Net assets of Biosergen AS from 2019 to 2025. This chart illustrates how Biosergen AS's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Biosergen AS to measure how much of total assets are equity-financed.
Annual Net Assets for Biosergen AS (2019–2025)
The table below shows the annual net assets of Biosergen AS from 2019 to 2025. For live market cap and overall valuation, see Biosergen AS market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr8.12 Million ≈ $873.52K |
-83.48% |
| 2024-12-31 | Skr49.14 Million ≈ $5.29 Million |
+2222.35% |
| 2023-12-31 | Skr2.12 Million ≈ $227.72K |
-90.72% |
| 2022-12-31 | Skr22.79 Million ≈ $2.45 Million |
+12.66% |
| 2021-12-31 | Skr20.23 Million ≈ $2.18 Million |
+285.22% |
| 2020-12-31 | Skr-10.92 Million ≈ $-1.18 Million |
-132.84% |
| 2019-12-31 | Skr-4.69 Million ≈ $-504.90K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biosergen AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3399491700.0% over the analyzed period, indicating profitable operations and earnings retention.
Biosergen AS Net Assets Breakdown (December 2025)
Biosergen AS net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr8.12 Million | 100.00% |
| Total Equity | Skr8.12 Million | 100.00% |
Biosergen AS Competitors by Market Cap
The table below lists competitors of Biosergen AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Haydale Graphene Industries
LSE:HAYD
|
$124.92K |
|
Enlivex Therapeutics Ltd
TA:ENLV
|
$126.77K |
|
Lexington Gold Ltd
LSE:LEX
|
$126.84K |
|
Safe Orthopaedics SA
PA:ALSAF
|
$127.51K |
|
The Investment Company plc
LSE:INV
|
$124.10K |
|
Sumo Resources PLC
PA:MLSUM
|
$124.00K |
|
IQ-AI LTD. LS -01
F:5Y1
|
$123.35K |
|
Marlowe plc
LSE:MRL
|
$122.94K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biosergen AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,208,000 to 8,117,000, a change of -40,091,000 (-83.2%).
- Net loss of 40,817,000 reduced equity.
- Other factors increased equity by 726,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-40.82 Million | -502.86% |
| Other Changes | Skr726.00K | +8.94% |
| Total Change | Skr- | -83.16% |
Book Value vs Market Value Analysis
This analysis compares Biosergen AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | Skr-2.26 | Skr0.49 | x |
| 2020-12-31 | Skr-42.02 | Skr0.49 | x |
| 2021-12-31 | Skr37.83 | Skr0.49 | x |
| 2022-12-31 | Skr43.20 | Skr0.49 | x |
| 2023-12-31 | Skr4.71 | Skr0.49 | x |
| 2024-12-31 | Skr20.09 | Skr0.49 | x |
| 2025-12-31 | Skr3.46 | Skr0.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biosergen AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -502.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.61x
- Recent ROE (-502.86%) is below the historical average (-305.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -412.48% | 0.20x | 0.00x | Skr-4.95 Million |
| 2020 | 0.00% | -162.95% | 0.92x | 0.00x | Skr-6.13 Million |
| 2021 | -170.80% | -403.10% | 0.29x | 1.46x | Skr-36.58 Million |
| 2022 | -149.37% | 0.00% | 0.00x | 1.48x | Skr-36.33 Million |
| 2023 | -1277.74% | 0.00% | 0.00x | 3.40x | Skr-27.25 Million |
| 2024 | -39.82% | 0.00% | 0.00x | 1.10x | Skr-24.02 Million |
| 2025 | -502.86% | 0.00% | 0.00x | 2.61x | Skr-41.63 Million |
Industry Comparison
This section compares Biosergen AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,426,563
- Average return on equity (ROE) among peers: -118.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biosergen AS (BIOSGN) | Skr8.12 Million | 0.00% | 1.61x | $124.84K |
| 2cureX AB (2CUREX) | $58.86 Million | -12.44% | 0.07x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $7.35 Million |
| AcouSort AB (ACOU) | $78.63K | -354.63% | 2.32x | $7.49 Million |
| Active Biotech AB (ACTI) | $55.60 Million | -67.09% | 0.26x | $11.63 Million |
| Alzinova AB (ALZ) | $123.82 Million | -16.60% | 0.08x | $7.32 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $76.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $13.71 Million | -366.46% | 0.39x | $4.83 Million |
| Alligator Bioscience AB (ATORX) | $468.31 Million | -32.04% | 0.09x | $1.10 Million |
| BioInvent International AB (BINV) | $885.82 Million | -48.47% | 0.12x | $26.95 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.49 Billion |
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.